Prof. Victor van Beusechem Presents New Clinical Study Data at ESGCT Congress in Brussels

October 2023

ORCA Therapeutics BV (“ORCA”), an innovator in the development of immuno-oncology therapies, is delighted to announce that Prof. van Beusechem has been invited to present new data from ORCA’s seminal clinical study on prostate cancer at the prestigious European Society of Gene and Cell Therapy (ESGCT) Congress, to be held in Brussels in October 2023.

Prof. van Beusechem, an acclaimed expert in the field of gene and cell therapy, will elucidate novel insights and interim results from the ongoing clinical study on prostate cancer conducted by ORCA Therapeutics. His presentation aims to shed light on transformative methodologies and prospective advancements in prostate cancer treatment and contribute significantly to the global scientific communication in the field.

About ORCA Therapeutics BV:
ORCA Therapeutics BV specializes in creating innovative immuno therapies focused on oncolytic viruses. The company is committed to transforming scientific discoveries into therapeutic solutions, addressing unmet medical needs and enhancing the quality of life for patients around the globe. For more details about ORCA Therapeutics BV, please visit

For More Information and Press Inquiries, Please Contact:

Kees Groen, PhD